AU2012318670B2 - Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication - Google Patents

Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication Download PDF

Info

Publication number
AU2012318670B2
AU2012318670B2 AU2012318670A AU2012318670A AU2012318670B2 AU 2012318670 B2 AU2012318670 B2 AU 2012318670B2 AU 2012318670 A AU2012318670 A AU 2012318670A AU 2012318670 A AU2012318670 A AU 2012318670A AU 2012318670 B2 AU2012318670 B2 AU 2012318670B2
Authority
AU
Australia
Prior art keywords
fee
pyridin
ylamino
pyrimidin
thiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012318670A
Other languages
English (en)
Other versions
AU2012318670A1 (en
Inventor
Timothy M. Block
Andrea Cuconati
Xiaodong Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BARUCH S BLUMBERG INSTITUTE
Drexel University
Original Assignee
BARUCH S BLUMBERG INST
Drexel University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BARUCH S BLUMBERG INST, Drexel University filed Critical BARUCH S BLUMBERG INST
Publication of AU2012318670A1 publication Critical patent/AU2012318670A1/en
Assigned to DREXEL UNIVERSITY, INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH reassignment DREXEL UNIVERSITY Request for Assignment Assignors: INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH
Assigned to DREXEL UNIVERSITY, BARUCH S. BLUMBERG INSTITUTE reassignment DREXEL UNIVERSITY Amend patent request/document other than specification (104) Assignors: DREXEL UNIVERSITY, INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH
Application granted granted Critical
Publication of AU2012318670B2 publication Critical patent/AU2012318670B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012318670A 2011-10-04 2012-10-04 Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication Ceased AU2012318670B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161542907P 2011-10-04 2011-10-04
US61/542,907 2011-10-04
PCT/US2012/058674 WO2013052613A1 (en) 2011-10-04 2012-10-04 Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication

Publications (2)

Publication Number Publication Date
AU2012318670A1 AU2012318670A1 (en) 2014-05-22
AU2012318670B2 true AU2012318670B2 (en) 2017-09-07

Family

ID=48044139

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012318670A Ceased AU2012318670B2 (en) 2011-10-04 2012-10-04 Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication

Country Status (13)

Country Link
US (2) US20140249154A1 (cg-RX-API-DMAC7.html)
EP (1) EP2763674A4 (cg-RX-API-DMAC7.html)
JP (2) JP6240078B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140071472A (cg-RX-API-DMAC7.html)
CN (1) CN103957908A (cg-RX-API-DMAC7.html)
AU (1) AU2012318670B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014007963A2 (cg-RX-API-DMAC7.html)
CA (1) CA2850779A1 (cg-RX-API-DMAC7.html)
HK (1) HK1200361A1 (cg-RX-API-DMAC7.html)
IL (1) IL231923A0 (cg-RX-API-DMAC7.html)
PH (1) PH12014500724A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201401207XA (cg-RX-API-DMAC7.html)
WO (1) WO2013052613A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9582896B2 (en) * 2011-09-02 2017-02-28 Qualcomm Incorporated Line tracking with automatic model initialization by graph matching and cycle detection
ES2672701T3 (es) 2012-11-07 2018-06-15 Karus Therapeutics Limited Nuevos inhibidores de histona deacetilasa y su uso en terapia
WO2014159938A1 (en) 2013-03-13 2014-10-02 The Broad Institute, Inc. Substituted aminothiazoles for the treatment of tuberculosis
PT2994465T (pt) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novos inibidores de histona desacetilase
WO2016046759A2 (en) 2014-09-22 2016-03-31 Fratagene Therapeutics Ltd. Compositions and methods for treating friedreich's ataxia
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
WO2016176396A1 (en) * 2015-04-29 2016-11-03 Foresight Biotherapeutics, Inc. Therapeutic combinations of antiviral and anti-inflammatory therapies
CN105524056A (zh) * 2016-01-05 2016-04-27 中山大学肿瘤防治中心 一种氨基噻唑化合物及其制备方法和应用
US10913734B2 (en) * 2016-07-11 2021-02-09 Baruch S. Blumberg Institute Substituted aminothiazoles
KR102795129B1 (ko) * 2017-06-22 2025-04-15 셀진 코포레이션 B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
WO2022087326A1 (en) * 2020-10-23 2022-04-28 Celgene Corporation Heterocyclic compounds and their use for treatment of helminthic infections and diseases
WO2025017207A1 (en) 2023-07-20 2025-01-23 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Inhibitors of smndc1 and their therapeutic use
WO2025151517A1 (en) * 2024-01-08 2025-07-17 Wavebreak Therapeutics Limited Thiazole compounds, compositions and methods of treating disorders associated with missfolding of alpha-synuclein protein

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015773A2 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
WO2005099673A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycylic thiazoles as potassium ion channel modulators
US7105550B2 (en) * 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
WO2008083098A1 (en) * 2006-12-27 2008-07-10 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
WO2009114552A1 (en) * 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl compounds, compositions, and methods of use in cancer treatment
WO2010111711A2 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561267A1 (en) * 2004-03-30 2005-10-20 Merck & Co., Inc. 2-aminothiazole compounds useful as aspartyl protease inhibitors
EA200702445A1 (ru) 2005-05-09 2008-04-28 Ачиллион Фармасьютикалз, Инк. Соединения тиазола и способы их применения
AU2007223797A1 (en) * 2006-03-08 2007-09-13 Achillion Pharmaceuticals, Inc. Substituted aminothiazole derivatives with anti-HCV activity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105550B2 (en) * 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
WO2003015773A2 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
WO2005099673A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycylic thiazoles as potassium ion channel modulators
WO2008083098A1 (en) * 2006-12-27 2008-07-10 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
WO2009114552A1 (en) * 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl compounds, compositions, and methods of use in cancer treatment
WO2010111711A2 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hay, M., et. al., "4-Pyridylanilinothiazoles That Selectively Target von Hippel-Lindau Deficient Renal Cell Carcinoma Cells by Inducing Autophagic Cell Death", Journal of Medicinal Chemistry, 2010, Vol. 53, No. 2, pages 787-797 *

Also Published As

Publication number Publication date
WO2013052613A1 (en) 2013-04-11
IL231923A0 (en) 2014-05-28
AU2012318670A1 (en) 2014-05-22
BR112014007963A2 (pt) 2013-04-11
EP2763674A4 (en) 2015-04-29
JP2017149753A (ja) 2017-08-31
US20170066758A1 (en) 2017-03-09
CN103957908A (zh) 2014-07-30
US10087173B2 (en) 2018-10-02
CA2850779A1 (en) 2013-04-11
US20140249154A1 (en) 2014-09-04
EP2763674A1 (en) 2014-08-13
HK1200361A1 (en) 2015-08-07
JP2014528450A (ja) 2014-10-27
SG11201401207XA (en) 2014-05-29
PH12014500724A1 (en) 2014-05-19
KR20140071472A (ko) 2014-06-11
JP6240078B2 (ja) 2017-11-29

Similar Documents

Publication Publication Date Title
AU2012318670B2 (en) Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication
ES2790830T3 (es) Formas solidas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico
ES2778846T3 (es) Moduladores heterocíclicos de transportadores de casete de unión a ATP
SG181523A1 (en) Therapeutic compounds and related methods of use
BR112020008851A2 (pt) composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
ZA200601460B (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune disease
BR112017016193B1 (pt) Derivados de 4h-pirrolo[3,2-c]piridin-4-ona
HUE035408T2 (en) Amino-substituted imidazo [1,2-a] pyridinecarboxamides and their use
HUE026170T2 (en) Substituted nicotinamides as modulators of KCNQ2 / 3
TW201300359A (zh) 新穎微管蛋白抑制劑
EP3436463A1 (en) Crystalline forms of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h- pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one hemihydrate
TW201245178A (en) Amide derivative and use thereof
EP3391885B1 (en) Therapeutic agent for breast cancer
EA029827B1 (ru) Производные бензимидазола и их фармацевтические композиции для лечения воспалительных заболеваний
JP2017535514A (ja) Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類
WO1996004914A1 (en) Triazine derivative and medicine
EP4323349A1 (en) Isoindolinone amide compounds useful to treat diseases associated with gspt1
TW200619195A (en) Phenylpyrrolidine dopamine D3 receptor antagonists
AU2013302319A1 (en) VEGFR3 inhibitors
EA022408B1 (ru) Производные санглиферина и способы их получения
Xu et al. Isostructurality Among Solvates of Cabazitaxel: X‐ray Structures and New Solvates Preparation
EP2970396A1 (en) Immunogenic human rhinovirus (hrv) compositions
EP3620455B1 (en) New preparation method for escitalopram pamoate
Caira et al. Relationships between structural and thermal properties of anhydrous and solvated crystalline forms of brodimoprim
RS65047B1 (sr) Novi kristalni oblici tienopirimidina kao inhibitori mcl-1

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH; DREXEL

Free format text: FORMER APPLICANT(S): INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired